SCHEMBL2224775

SCHEMBL2224775

COc1c(C)cc(-c2nc3cnc(Cl)nc3o2)cc1C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 1/20 0.48
ALDH1A1 P00352 5/20 0.37
KDM4E B2RXH2 4/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
APP P05067 5/20 0.35
HPGD P15428 5/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
NFKB1 P19838 2/20 0.35
NFKB2 Q00653 2/20 0.35
RELA Q04206 2/20 0.35
TP53 P04637 1/20 0.35
HSD17B10 Q99714 1/20 0.35
MAOB P27338 2/20 0.32
PDGFRB P09619 1/20 0.32
PDGFRA P16234 1/20 0.32
ESR1 P03372 1/20 0.32
ESR2 Q92731 1/20 0.32
GAA P10253 1/20 0.32
DHFR P00374 1/20 0.32
ALOX5 P09917 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2223548 0.83 S1PR1 (0.42) S1PR1ALDH1A1KDM4ESMN1; SMN2APP
SCHEMBL2224907 0.82 S1PR1 (0.42) S1PR1ALDH1A1KDM4ESMN1; SMN2APP
SCHEMBL14486171 0.80 APP (0.44) S1PR1ALDH1A1KDM4ESMN1; SMN2APP
SCHEMBL14486843 0.78 SMN1; SMN2 (0.40) S1PR1ALDH1A1KDM4ESMN1; SMN2APP
SCHEMBL14797044 0.78 S1PR1 (0.52) S1PR1ALDH1A1KDM4EHPGDTP53
SCHEMBL2228763 0.77 S1PR1 (0.64) S1PR1ALDH1A1KDM4ESMN1; SMN2HPGD
SCHEMBL2225593 0.74 S1PR1 (0.52) S1PR1ALDH1A1KDM4EAPPHPGD
SCHEMBL2225370 0.74 S1PR1 (0.58) S1PR1ALDH1A1KDM4ESMN1; SMN2HPGD
SCHEMBL9932139 0.72 SMN1; SMN2 (0.47) KDM4ESMN1; SMN2HPGDMAOBMAPT
SCHEMBL9931268 0.71 PIK3CB (0.42) ALDH1A1KDM4ESMN1; SMN2APPHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2729475-B1 Carboxylic acid derivatives with an oxazolo[4,5-d]pyrimidine ring SANOFI SA (FR) 2015-06-10 EP disclosed
EP-2729475-B1 Carboxylic acid derivatives with an oxazolo[4,5-d]pyrimidine ring SANOFI SA (FR) 2015-06-10 EP disclosed
US-9040544-B2 2,5-substituted oxazolopyrimidine derivatives SANOFI (FR) 2015-05-26 US disclosed
US-8846692-B2 Carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring SANOFI (FR) 2014-09-30 US disclosed
US-8846690-B2 Heterocyclic carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring SANOFI (FR) 2014-09-30 US disclosed
EP-2523963-B1 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES AS EDG-1 AGONISTS SANOFI SA (FR) 2014-08-27 EP disclosed
US-8735402-B2 Cycloalkyloxycarboxylic acid derivatives SANOFI (FR) 2014-05-27 US disclosed
US-8735402-B2 Cycloalkyloxycarboxylic acid derivatives SANOFI (FR) 2014-05-27 US disclosed
US-8735402-B2 Cycloalkyloxycarboxylic acid derivatives SANOFI (FR) 2014-05-27 US disclosed
EP-2729475-A1 CARBOXYLIC ACID DERIVATIVES HAVING AN OXAZOLO[4,5-C]PYRIDINE RING SANOFI (FR) 2014-05-14 EP disclosed
US-20130023545-A1 CYCLOALKYLOXYCARBOXYLIC ACID DERIVATIVES SANOFI (FR) 2013-01-24 US disclosed
US-20130023545-A1 CYCLOALKYLOXYCARBOXYLIC ACID DERIVATIVES SANOFI (FR) 2013-01-24 US disclosed
WO-2013004828-A1 CARBOXYLIC ACID DERIVATIVES HAVING AN OXAZOLO[4,5-C]PYRIDINE RING SANOFI (FR) 2013-01-10 WO disclosed
WO-2013004828-A1 CARBOXYLIC ACID DERIVATIVES HAVING AN OXAZOLO[4,5-C]PYRIDINE RING SANOFI (FR) 2013-01-10 WO disclosed
EP-2523962-A1 CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING SANOFI (FR) 2012-11-21 EP disclosed
EP-2523960-A1 HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING SANOFI (FR) 2012-11-21 EP disclosed
EP-2523963-A1 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES SANOFI (FR) 2012-11-21 EP disclosed
WO-2011086080-A1 HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING SANOFI-AVENTIS (FR) 2011-07-21 WO disclosed
WO-2011086079-A1 CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING SANOFI-AVENTIS (FR) 2011-07-21 WO disclosed
WO-2011086081-A1 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES SANOFI-AVENTIS (FR) 2011-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023545-A1 CYCLOALKYLOXYCARBOXYLIC ACID DERIVATIVES C3AR1, CCR2, C5 S1PR1 233/4885ALDH1A1 214/4885KDM4E 1550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.